

Change of Director's Interest Notices – James Graham

Sydney Australia, 26 June 2023: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to provide a notice of change of interests in Director holdings.

The Company advises that Chief Executive Officer James Graham has increased his shareholding through the on-market purchase of an additional 500,000 shares totalling AUD \$306,871.75.

19 th June – 22 nd June 2023			
Person whose relevant interest changed Price per share Qu		Quantity On	Value (\$)
James Graham (CEO & Managing Director)	0.566419	89,303	\$ 50,582.92
	0.621541	248,955	\$ 154,735.74
	0.62980	80,403	\$ 50,637.81
	0.625964	81,339	\$ 50,915.29

Total	500,000	\$ 306,871.75

This announcement has been approved for release by Recce Pharmaceuticals Board.



Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Recce Pharmaceuticals Ltd (Company)
ACN	124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Graham
Date of last notice	22 June 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Buttonwood Nominees Pty Ltd with the shares being held on behalf of James Graham	
Date of change	a) 25 August 2022 (transfer) b) 25 August 2022 (transfer) c) 15 June 2023 (transfer) d) 19 June 2023 e) 20 June 2023 f) 21 June 2023 g) 22 June 2023	

01/01/2011 Appendix 3Y Page 1

⁺ See chapter 19 for defined terms.

No. of securities held prior to change	Direct Interest
No. or securities field prior to change	1. 2,840,332 fully paid ordinary
	shares
	2. 389,712 Class B Performance
	Shares
	3. 2,250,000 Unlisted Options
	, ,
	Indirect Interest
	Mr. James Graham < J Graham Family A/c>
	1. 2,493,750 fully paid ordinary
	shares
	2. 356,250 Class B Performance
	Shares
	Bulleen Pty Ltd
	1. 697,850 fully paid ordinary shares
	1. 077,030 fully paid of diffially shares
Class	Fully paid ordinary shares
Number acquired	500,000 fully paid ordinary shares
Number disposed	Nil
Number disposed	INII
Value/Consideration	a) \$50,582.92
Note: If consideration is non-cash, provide details and estimated valuation	b) \$154,735.74
valuation	c) \$50,637.81
	d) \$50,915.29
No. of securities held after change	Total number of fully paid ordinary shares
	held after change: 6,531,932
	Diversit Interest
	Direct Interest
	 262,347 fully paid ordinary shares 389,712 Class B Performance
	Shares
	3. 2,250,000 Unlisted Options
	5. 2,250,000 omisted options
	Indirect Interest
	Mr. James Graham < J Graham Family A/c>
	1. 356,250 Class B Performance
	Shares
	Bulleen Pty Ltd
	1. 769,585 fully paid ordinary shares
	Buttonwood Nominees Pty Ltd
	1. 5,500,000 fully paid ordinary
	shares
	5 55

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	1. (a) to (c) transfer of securities between entities controlled by Mr Graham with no change to Mr Graham's relevant interest.
	2. (d) to (g) on-market purchases

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)	
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

01/01/2011 Appendix 3Y Page 3

⁺ See chapter 19 for defined terms.